Medications that improve pain threshold can be useful in the pharmacotherapy of
Parkinson's disease (PD). Pain is a prevalent PD's non-motor symptom with a higher …

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

The nonpsychoactive phytocannabinoid cannabidiol (CBD) has been shown to have
analgesic effects in animal studies but little is known about its mechanism of action. We …

The incidence of chronic pain is high in the general population and it is closely related to
anxiety disorders, which promote negative effects on the quality of life. The cannabinoid …

The psychoactive and non-psychoactive constituents of cannabis, Δ9-tetrahydrocannabinol
(THC) and cannabidiol (CBD), have synergistic analgesic efficacy in animal models of …

The prelimbic division (PrL) of the medial prefrontal cortex (mPFC) is a cerebral division that
is putatively implicated in the chronic pain and depression. We investigated the activity of …

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …

Preclinical studies have demonstrated the analgesic potential of cannabidiol (CBD). Those
suggesting an effect on pain-processing receptors have brought CBD back into focus. This …

Cannabis and its psychoactive constituent D9-tetrahydrocannabinol (THC) have efficacy
against neuropathic pain, however, this is hampered by their side effects. It has been …

Background and purpose: A nonpsychoactive constituent of the cannabis plant, cannabidiol
has been demonstrated to have low affinity for both cannabinoid CB1 and CB2 receptors …